Philips Healthcare has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of its CT product suite in low-dose lung cancer screening.
The FDA clearance encompasses the vendor's suite of 27 CT and PET/CT scanners, as well as integrated software and services. Philips said healthcare organizations of all sizes can now utilize existing systems to implement low-dose CT lung cancer screening programs.
Philips highlighted a number of benefits from its lung cancer screening technology, including dose-management software, "control center" software that provides referring physicians with digital access to patient-tracking data, and image data sharing and analytics capabilities via its IntelliSpace Portal software.
The vendor also said that version 8.0 of IntelliSpace Portal now includes its CT Lung Nodule Assessment application.
